Juvaris BioTherapeutics Announces Strategic Collaboration with Antigen Discovery Inc.

Published: Jun 29, 2009

BURLINGAME, Calif.--(BUSINESS WIRE)--Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, today announced the signing of a definitive agreement with Antigen Discovery, Inc. (ADi) to access ADi’s proprietary high-throughput protein microarray screening system to discover novel disease-specific antigens to fuel Juvaris’ vaccine pipeline. Juvaris will sponsor research for multiple disease targets and pay ADi upfront payments, development milestones and royalties on licensed products in exchange for full product development rights to all fields except diagnostics, which will belong to ADi.

Back to news